Literature DB >> 2899596

CD11a-c/CD18 and GP84 (LB-2) adhesion molecules on human large granular lymphocytes and their participation in natural killing.

T Timonen1, M Patarroyo, C G Gahmberg.   

Abstract

Effect of mAb against the CD11a-c, CD18, and GP84 adhesion molecules on the binding and cytotoxicity of human NK cells was studied. The target cells were K562, MOLT-4, Raji, and fresh uncultured autologous endometrial carcinoma cells. Antibodies against adhesion relevant epitopes of CD11a(TA-1/LFA-1), CD11b(Mol/OKM1/Mac1), or CD11c (Leu-M5) did not inhibit NK function. The mAb 60.3 against CD18, the common beta-chain associated to CD11a-c, strongly inhibited both the binding and cytotoxicity of large granular lymphocytes (LGL) against all the target cells tested. Also the antibody LB-2 against the GP84 adhesion molecule inhibited NK function to some degree. 60.3 and LB-2 antibodies exerted an additive effect in the inhibition of both binding and cytotoxicity. However, even this antibody combination did not completely block NK activity, suggesting a heterogeneity of adhesion structures in the NK system. According to both FACS analyses and immunoprecipitation studies, all the tested antibodies recognized either a subpopulation or all of LGL. On the other hand, antibodies against CD11b, CD11c, and LB-2 showed only marginal reactivity with highly purified LGL-free T cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2899596

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

1.  Adhesion and activation molecules expressed by human natural killer cells.

Authors:  A Santoni; A Gismondi; R Paolini; A Procopio; S Morrone; F Mainiero; G Santoni; M Piccoli; L Frati
Journal:  Cytotechnology       Date:  1991-02       Impact factor: 2.058

2.  Antigen shedding and metastasis of tumour cells.

Authors:  S K Law
Journal:  Clin Exp Immunol       Date:  1991-07       Impact factor: 4.330

3.  CD27/CD70 interaction directly induces natural killer cell killing activity.

Authors:  F C Yang; K Agematsu; T Nakazawa; T Mori; S Ito; T Kobata; C Morimoto; A Komiyama
Journal:  Immunology       Date:  1996-06       Impact factor: 7.397

4.  Massive production of Th2 cytokines by human CD4+ effector T cells transiently expressing the natural killer cell marker CD57/HNK1.

Authors:  V Brinkmann; C Kristofic
Journal:  Immunology       Date:  1997-08       Impact factor: 7.397

Review 5.  Leucocyte adhesion deficiency.

Authors:  M H el Habbal; S Strobel
Journal:  Arch Dis Child       Date:  1993-10       Impact factor: 3.791

6.  Leukocyte-mediated lysis of infected hepatocytes during listeriosis occurs in mice depleted of NK cells or CD4+ CD8+ Thy1.2+ T cells.

Authors:  J W Conlan; P L Dunn; R J North
Journal:  Infect Immun       Date:  1993-06       Impact factor: 3.441

7.  A role for plasmacytoid dendritic cells in the rapid IL-18-dependent activation of NK cells following HSV-1 infection.

Authors:  Daniel P Barr; Gabrielle T Belz; Patrick C Reading; Magdalena Wojtasiak; Paul G Whitney; William R Heath; Francis R Carbone; Andrew G Brooks
Journal:  Eur J Immunol       Date:  2007-05       Impact factor: 5.532

8.  Expression of adhesion molecules on acute leukemic blast cells and sensitivity to normal LAK activity.

Authors:  D Raspadori; F Lauria; M A Ventura; D Rondelli; S Tura
Journal:  Ann Hematol       Date:  1993-11       Impact factor: 3.673

9.  Resistance of HER2/neu-overexpressing tumor targets to lymphokine-activated-killer-cell-mediated lysis: evidence for deficiency of binding and post-binding events.

Authors:  C Fady; A Gardner; J F Gera; A Lichtenstein
Journal:  Cancer Immunol Immunother       Date:  1993-05       Impact factor: 6.968

10.  PI3K links NKG2D signaling to a CrkL pathway involved in natural killer cell adhesion, polarity, and granule secretion.

Authors:  Colin M Segovis; Renee A Schoon; Christopher J Dick; Lucas P Nacusi; Paul J Leibson; Daniel D Billadeau
Journal:  J Immunol       Date:  2009-06-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.